Heron Therapeutics Inc (HRTX)

Over the past six months, Heron Therapeutics' stock price has been impacted by several events. The share price declined by 55.40% between April 8, 2025, and April 7, 2026. On February 26, 2026, the company announced its Q4 2025 financial results, reporting a GAAP EPS of -$0.02 and revenue of $40.59 million, exceeding market expectations, which led to an 11.1% stock gain. Preliminary unaudited Q4 and full-year 2025 net revenues were announced on January 9, 2026, with ZYNRELEF being the largest contributor to Q4 growth. In December 2025, APONVIE was included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV). On November 4, 2025, the company announced its Q3 2025 financial results, reporting a net loss of $17.5 million, impacted by an $11.3 million loss due to debt extinguishment. In August 2025, Heron Therapeutics completed a capital restructuring, reducing total debt and extending debt maturities.

Demand for Heron Therapeutics' products exhibits product-specific trends rather than a clear overarching seasonal pattern. ZYNRELEF has shown strong and increasing demand, driven by commercial initiatives. APONVIE has also experienced substantial growth in net revenue, with increased adoption in hospital systems. CINVANTI unit demand and net revenue increased in Q3 2025 compared to Q3 2024. SUSTOL sales declined in Q4 2025, and the company is considering discontinuing its marketing. In October 2024, there was a potential for increased demand for CINVANTI, SUSTOL, and APONVIE as alternatives during a temporary shortage of intravenous fluids.

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care through innovative therapeutic solutions, operating within the Healthcare sector, specifically in Biotechnology, Drug Discovery, and Pharmaceutical Preparation Manufacturing. The company focuses on acute care and oncology supportive care, with FDA-approved products including ZYNRELEF for postoperative pain management, APONVIE for the prevention of postoperative nausea and vomiting, CINVANTI for chemotherapy-induced nausea and vomiting, and SUSTOL for nausea and vomiting associated with chemotherapy.

Heron Therapeutics is headquartered in Cary, North Carolina, and primarily serves the U.S. market while pursuing global partnerships to expand its reach.

Heron Therapeutics' brand reputation has seen positive developments related to product performance and recognition. ZYNRELEF and APONVIE have shown strong revenue growth, with ZYNRELEF experiencing a "breakout quarter" in Q4 2025. The inclusion of APONVIE in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) highlights its clinical impact. Analyst ratings for HRTX are mixed, with some sources indicating a consensus "Hold" and others a "Strong Buy" with significant upside potential.

Heron Therapeutics has a diverse ownership structure. Institutional investors hold a significant portion of the company's stock, approximately 80.01%. Insiders own around 5.86% to 21.29% of the stock, and retail investors hold approximately 0.00% to 11.27%. Major institutional owners include Rubric Capital Management LP, Clearline Capital LP, Adage Capital Partners Gp, L.l.c., BlackRock, Inc., Vanguard Group Inc, Velan Capital Investment Management LP, Millennium Management Llc, Palisade Capital Management Llc/nj, Tang Capital Management Llc and Tejara Capital Ltd.